Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy

一种磷酸二酯酶、抑制剂的技术，应用在医药,兽药领域，能够解决供需无法匹配、增加心脏收缩壁压力、LV肥厚恶化等问题

Inactive Publication Date: 2011-10-19
BOEHRINGER LNGELHEIM VETMEDICA GMBH
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

LV outflow obstruction caused by systolic protrusion of the mitral valve or hypertrophy at the top of the interventricular septum increases systolic wall pressure and increases myocardial oxygen demand, resulting in a mismatch between supply and demand, exacerbating LV hypertrophy, and accelerating diastolic dysfunction, heart rhythm Irregularity and eventual disease progression over time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
  • Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Treatment of Cats with HCM

[0062] A 15-year-old castrated male hybrid cat (maternal: Persian, paternal: European short-haired, weight: 6 kg) was brought into the veterinary clinic in March 2008. The animal was lethargic and immobile. Cardiovascular system tests showed acute circulatory failure with tachycardia (>180bpm). An electrocardiogram showed thickening of the left ventricular wall and septum, which is associated with HCM.

[0063] Furosemide (1mg / kg i.v) was given immediately, but the condition was not adequately controlled. In critical situations, 1.25 mg of pimobendan was administered orally in the expectation / fear that this measure might / would further aggravate the cat's condition.

[0064] Surprisingly, clinical signs improved and the cat awoke within hours. The veterinarian decided to continue the treatment with pimobendan at a dose of 20 mg / kg / day orally, since the owner had observed that the cat was abnormally inactive prior to acute crisis and tende...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and / or Ca2+- sensitizing agent or a pharmaceutically acceptable derivative thereof for the treatment of a patient suffering from hypertrophic cardiomyopathy (HCM). According to another aspect the present invention relates to the use of a PDE III inhibitor and / or Ca2+-sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from HCM.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the field of veterinary medicine. The present invention relates to inhibitors of phosphodiesterase type III (PDE III), Ca 2+ A sensitizer or a pharmaceutically acceptable derivative thereof. Background of the invention [0002] Hypertrophic cardiomyopathy (HCM) is the most common heart disease in cats and the most common cause of heart failure in this species (Riesen et al., 2007; Rush et al., 1998). Although genetic mutations in one or more of the sarcomeric proteins have been proposed to be responsible for most cats with HCM, only one specific mutation has been identified in Maine coon and Ragdoll cats (Meurs et al., 2005 and 2007; Kittleson et al., 1999). Cardiac disease is the ultimate cause of death in most cats identified with HCM. HCM is classified together with restrictive cardiomyopathy (RCM) as diastolic dysfunction. [0003] Five common phenotypic symptoms of feline HCM in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/10A61K31/277A61K31/4166A61K31/4178A61K31/4412A61K31/444A61K31/501A61K31/635A61P9/04
CPCA61K31/00A61K31/10A61K31/277A61K31/33A61K31/4166A61K31/4178A61K31/4412A61K31/444A61K31/501A61K31/635A61P9/00A61P9/04A61P43/00C07D237/04C07D403/04A61K2300/00
Inventor 于尔根·戴姆根奥拉夫·乔恩斯
Owner BOEHRINGER LNGELHEIM VETMEDICA GMBH
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com